NervGen Pharma
Develops NVG-291 for spinal-cord injury.
Something off on this page? Send us feedback.
Profile
NVG-291 is a neuroreparative peptide in clinical development for spinal-cord injury, alongside next-generation candidate NVG-300. A Vancouver-based, pre-commercial developer, NervGen relies on licensed Case Western science, clinical progress and capital formation.
Advances NVG-291, a subcutaneously administered neuroreparative peptide for spinal-cord injury. The active program includes the CONNECT SCI study, a planned RESTORE registrational study in chronic tetraplegia, and next-generation candidate NVG-300.
Operates as a Vancouver-based clinical-stage developer built around an exclusive worldwide license to patented Case Western Reserve University technology. That license covers research, development and commercialization for spinal-cord injury and other nerve-damage conditions.
Remains clinical-stage rather than commercial, with no approved product or product revenue. The business depends on clinical development, regulatory milestones under the license, and capital raised to advance NVG-291 and corporate operations.
Company facts
Key statistics
Year to date −61.4% · Average volume (30d) 489.7K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026Q2 FY26 | −$0.06 | −$0.37 | −510.8% | $4.5K | — | — | 0.00% |
| May 18, 2026Q1 FY26 | −$0.07 | −$0.01 | +80.4% | $4.5K | — | — | −2.20% |
| Mar 31, 2026Q4 FY25 | −$0.11 | −$0.26 | −125.8% | — | — | — | +15.65% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | −$10.0K | −$10.1K | −$10.0K | $21.5K | −$10.2K | −$10.3K | |
| Operating income | −$4.3M | −$4.7M | −$4.4M | −$8.4M | −$5.5M | −$9.0M | |
| Net income | −$2.8M | −$6.6M | −$3.0M | −$22.8M | −$1.2M | −$21.6M | |
| Diluted EPS | −$0.04 | −$0.09 | −$0.04 | −$0.32 | −$0.02 | −$0.24 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $62.5M · Total debt $0 · Total assets $65.0M · Shareholders' equity $12.4M
Dividends
No dividends on record.
Ownership
Shares outstanding 82.19M · Float 64.35M · 78.3% free float
Insiders — no current Form 4 position.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| PFG Investments, LLC | 201.0K | 0.24% | 13F | Apr 27, 2026 |
| Bank of America Corp /DE/ | 200.7K | 0.24% | 13F | May 18, 2026 |
| Marshall Wace, LLP | 200.4K | 0.24% | 13F | May 15, 2026 |
| Royal Bank of Canada | 172.0K | 0.21% | 13F | May 15, 2026 |
| Integrated Wealth Concepts LLC | 86.8K | 0.11% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Lineage Cell Therapeutics
Cell-replacement program for subacute and chronic spinal-cord injury
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| NervGen Pharma | $2.27 | 0.00% | $187.4M | — | — | — | — |
| Lineage Cell Therapeutics | $1.11 | −0.45% | $276.7M | — | — | 21.2 | −61.3% |
| Median | — | — | 21.2 | −61.3% |